Glenmark Pharmaceuticals Limited — Updates, 03-03-2025: Press Release

Glenmark Pharmaceuticals Inc., USA has successfully acquired and launched Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials, positioning itself in a competitive market with a proven therapeutic equivalent to Acetadote® Injection. The acquisition of the ANDA from Aspen Pharma USA Inc. opens a new revenue opportunity in the injectable space, with the Acetadote® market recording sales of approximately $15.2 million annually as of January 2025. This move enhances Glenmark's injectable portfolio in the U.S. market, where a focus on the hospital segment is expected to drive growth. The launch signifies strategic alignment with Glenmark’s commitment to expanding its product range and strengthens its market presence. Investors should consider this development as a potential growth catalyst for Glenmark, reflecting a positive outlook as the company continues to innovate and diversify its offerings.